12/12/06

Tanzania to launch new malaria treatment strategy

By: Timothy Kitundu

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Tanzania to launch new malaria treatment strategy</h1>
<h4>By: Timothy Kitundu</h4>
</div>
<br />
<br />

<div id="article-body">
<p>[DAR ES SALAAM] This week Tanzania will launch a fresh strategy to fight malaria by using a new drug that scientists believe can help halve the disease’s incidence and mortality rate by 2010.</p>
<p>The new drug, called ALU, is a combination of the antimalarials artemether and lumefantrine. It will be used together with older drug treatments, some of which have become inefficient at curing the disease.</p>
<p>The health policy will be launched on Friday (15 December).</p>
<p>Every year Tanzania loses an estimated US$10 billion — 3.4 per cent of its gross domestic product — directly or indirectly due to malaria.</p>
<p>ALU is meant to combat malaria parasites that have developed resistance to the drugs chloroquine and sulphurdoxine pyrimethamine, according to Alex Mwita, manager of Tanzania’s National Malaria Control Programme.</p>
<p>"Changing national drug policy remains a sensitive issue that cannot be done overnight," Mwita told SciDev.Net. "However, formulation of the policy systematically involved all stakeholders at all stages."</p>
<p>But Zul Premji, a malaria researcher at the Muhimbili University College of Health Sciences, warns that while ALU is highly effective, it is more expensive than SP and requires a rather high dosage. This could make it difficult for the poor to afford.</p>
<p>The new strategy will stress the proper administration of the drug, a crucial factor in countering drug resistance in the malaria parasite.</p>
<p>To be efficient, ALU must be taken for three consecutive days, and should not be discontinued, even if the patient feels better before that time.</p>
<p>Meanwhile, trials are ongoing for a malaria vaccine that has yielded successful results in the Gambia and Mozambique (see ‘<a target="_self" href="/News/index.cfm?fuseaction=readnews&itemid=1669&language=1" rel="noopener noreferrer">Malaria vaccine shows promising results in children</a>‘).</p>
<p>The vaccine is said to prevent 70 to 80 per cent of cases of malaria in children under the age of one, and lasts for two years. The results of trials carried out in Mozambique and the Gambia were published in The Lancet last year.</p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/sub-saharan-africa/news/tanzania-to-launch-new-malaria-treatment-strategy-ssa/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/sub-saharan-africa/news/tanzania-to-launch-new-malaria-treatment-strategy-ssa/",null,true])
</script>
</div>

[DAR ES SALAAM] This week Tanzania will launch a fresh strategy to fight malaria by using a new drug that scientists believe can help halve the disease’s incidence and mortality rate by 2010.

The new drug, called ALU, is a combination of the antimalarials artemether and lumefantrine. It will be used together with older drug treatments, some of which have become inefficient at curing the disease.

The health policy will be launched on Friday (15 December).

Every year Tanzania loses an estimated US$10 billion — 3.4 per cent of its gross domestic product — directly or indirectly due to malaria.

ALU is meant to combat malaria parasites that have developed resistance to the drugs chloroquine and sulphurdoxine pyrimethamine, according to Alex Mwita, manager of Tanzania’s National Malaria Control Programme.

"Changing national drug policy remains a sensitive issue that cannot be done overnight," Mwita told SciDev.Net. "However, formulation of the policy systematically involved all stakeholders at all stages."

But Zul Premji, a malaria researcher at the Muhimbili University College of Health Sciences, warns that while ALU is highly effective, it is more expensive than SP and requires a rather high dosage. This could make it difficult for the poor to afford.

The new strategy will stress the proper administration of the drug, a crucial factor in countering drug resistance in the malaria parasite.

To be efficient, ALU must be taken for three consecutive days, and should not be discontinued, even if the patient feels better before that time.

Meanwhile, trials are ongoing for a malaria vaccine that has yielded successful results in the Gambia and Mozambique (see ‘Malaria vaccine shows promising results in children‘).

The vaccine is said to prevent 70 to 80 per cent of cases of malaria in children under the age of one, and lasts for two years. The results of trials carried out in Mozambique and the Gambia were published in The Lancet last year.